The endothelin receptor antagonist tezosentan improves renal microcirculation in a porcine model of endotoxemic shock

Acta Anaesthesiologica Scandinavica

Volumn 52, Issue 10, 2008, Pages 1385-1393

  Fenhammar, J ^a,b   Andersson, A ^a,b   Frithiof, R ^b   Forestier, J ^a,b   Weitzberg, E ^b   Sollevi, A ^a,b   Hjelmqvist, H ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ATROPINE; ENDOTHELIN 1; FENTANYL; INTERLEUKIN 10; INTERLEUKIN 6; KETAMINE; MIDAZOLAM; PANCURONIUM BROMIDE; TEZOSENTAN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CREATININE BLOOD LEVEL; ENDOTOXEMIA; FEMALE; KIDNEY BLOOD FLOW; KIDNEY CIRCULATION; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; SEPTIC SHOCK; SWINE;

ALDOSTERONE; ANGIOTENSIN II; ANIMALS; DISEASE MODELS, ANIMAL; ENDOTOXEMIA; FEMALE; HEMODYNAMICS; INTERLEUKINS; KIDNEY; MICROCIRCULATION; OSMOLAR CONCENTRATION; PYRIDINES; RANDOM ALLOCATION; RECEPTORS, ENDOTHELIN; SWINE; TETRAZOLES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VASODILATOR AGENTS;

EID: 54049142053     PISSN: 00015172     EISSN: 13996576     Source Type: Journal    
DOI: 10.1111/j.1399-6576.2008.01768.x     Document Type: Article

References (45)

1. Neveu H, Kleinknecht D, Brivet F, Loirat P, Landais P. Prognostic factors in acute renal failure due to sepsis. Results of a prospective multicentre study. The French Study Group on Acute Renal Failure. Nephrol Dial Transplant 1996 11 : 293 9.
2. Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Regnier B. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 1995 274 : 968 74.
3. Yasuda H, Yuen PS, Hu X, Zhou H, Star RA. Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. Kidney Int 2006 69 : 1535 42.
4. Molitoris BA, Sutton TA. Endothelial injury and dysfunction: role in the extension phase of acute renal failure. Kidney Int 2004 66 : 496 9.
5. Pittet JF, Morel DR, Hemsen A, Gunning K, Lacroix JS, Suter PM, Lundberg JM. Elevated plasma endothelin-1 concentrations are associated with the severity of illness in patients with sepsis. Ann Surg 1991 213 : 261 4.
6. Tschaikowsky K, Sagner S, Lehnert N, Kaul M, Ritter J. Endothelin in septic patients: effects on cardiovascular and renal function and its relationship to proinflammatory cytokines. Crit Care Med 2000 28 : 1854 60.
7. Koch T, Geiger S, Ragaller MJ. Monitoring of organ dysfunction in sepsis/systemic inflammatory response syndrome: novel strategies. J Am Soc Nephrol 2001 12 (Suppl. 17) : S53 9.
8. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988 332 : 411 5.
9. Laghmani K, Preisig PA, Alpern RJ. The role of endothelin in proximal tubule proton secretion and the adaptation to a chronic metabolic acidosis. J Nephrol 2002 15 (Suppl. 5) : S75 87.
10. Denton KM, Shweta A, Finkelstein L, Flower RL, Evans RG. Effect of endothelin-1 on regional kidney blood flow and renal arteriole calibre in rabbits. Clin Exp Pharmacol Physiol 2004 31 : 494 501.
11. Konrad D, Oldner A, Rossi P, Wanecek M, Rudehill A, Weitzberg E. Differentiated and dose-related cardiovascular effects of a dual endothelin receptor antagonist in endotoxin shock. Crit Care Med 2004 32 : 1192 9.
12. Rossi P, Wanecek M, Konrad D, Oldner A. Tezosentan counteracts endotoxin-induced pulmonary edema and improves gas exchange. Shock 2004 21 : 543 8.
13. Urbanowicz W, Sogni P, Moreau R, Tazi KA, Barriere E, Poirel O, Martin A, Guimont MC, Cazals-Hatem D, Lebrec D. Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats. Gut 2004 53 : 1844 9.
14. Chin A, Radhakrishnan J, Fornell L, John E. Effects of tezosentan, a dual endothelin receptor antagonist, on the cardiovascular and renal systems of neonatal piglets during endotoxic shock. J Pediatr Surg 2002 37 : 482 7.
15. Krejci V, Hiltebrand LB, Erni D, Sigurdsson GH. Endothelin receptor antagonist bosentan improves microcirculatory blood flow in splanchnic organs in septic shock. Crit Care Med 2003 31 : 203 10.
16. Heyman SN, Darmon D, Goldfarb M, Bitz H, Shina A, Rosen S, Brezis M. Endotoxin-induced renal failure. I. A role for altered renal microcirculation. Exp Nephrol 2000 8 : 266 74.
17. Wanecek M, Rudehill A, Hemsen A, Lundberg JM, Weitzberg E. The endothelin receptor antagonist, bosentan, in combination with the cyclooxygenase inhibitor, diclofenac, counteracts pulmonary hypertension in porcine endotoxin shock. Crit Care Med 1997 25 : 848 57.
18. Mitaka C, Hirata Y, Yokoyama K, Nagura T, Tsunoda Y, Amaha K. Improvement of renal dysfunction in dogs with endotoxemia by a nonselective endothelin receptor antagonist. Crit Care Med 1999 27 : 146 53.
19. Oldner A, Wanecek M, Goiny M, Weitzberg E, Rudehill A, Alving K, Sollevi A. The endothelin receptor antagonist bosentan restores gut oxygen delivery and reverses intestinal mucosal acidosis in porcine endotoxin shock. Gut 1998 42 : 696 702.
20. Clozel M, Ramuz H, Clozel JP, Breu V, Hess P, Loffler BM, Coassolo P, Roux S. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther 1999 290 : 840 6.
21. Motte S, McEntee K, Naeije R. Endothelin receptor antagonists. Pharmacol Ther 2006 110 : 386 414.
22. Cunningham ME, Huribal M, Bala RJ, McMillen MA. Endothelin-1 and endothelin-4 stimulate monocyte production of cytokines. Crit Care Med 1997 25 : 958 64.
23. Browatzki M, Schmidt J, Kubler W, Kranzhofer R. Endothelin-1 induces interleukin-6 release via activation of the transcription factor NF-kappa B in human vascular smooth muscle cells. Basic Res Cardiol 2000 95 : 98 105.
24. Cunningham PN, Dyanov HM, Park P, Wang J, Newell KA, Quigg RJ. Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J Immunol 2002 168 : 5817 23.
25. Simmons EM, Himmelfarb J, Sezer MT, Chertow GM, Mehta RL, Paganini EP, Soroko S, Freedman S, Becker K, Spratt D, Shyr Y, Ikizler TA. Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int 2004 65 : 1357 65.
26. Smits GJ, Roman RJ, Lombard JH. Evaluation of laser-Doppler flowmetry as a measure of tissue blood flow. J Appl Physiol 1986 61 : 666 72.
27. Hemsen A. Biochemical and functional characterization of endothelin peptides with special reference to vascular effects. Acta Physiol Scand 1991 602 (Suppl.) : 1 61.
28. Boerma EC, van der Voort PH, Spronk PE, Ince C. Relationship between sublingual and intestinal microcirculatory perfusion in patients with abdominal sepsis. Crit Care Med 2007 35 : 1055 60.
29. De Backer D, Creteur J, Dubois MJ, Sakr Y, Koch M, Verdant C, Vincent JL. The effects of dobutamine on microcirculatory alterations in patients with septic shock are independent of its systemic effects. Crit Care Med 2006 34 : 403 8.
30. Bourgoin A, Leone M, Delmas A, Garnier F, Albanese J, Martin C. Increasing mean arterial pressure in patients with septic shock: effects on oxygen variables and renal function. Crit Care Med 2005 33 : 780 6.
31. Faivre V, Kaskos H, Callebert J, Losser MR, Milliez P, Bonnin P, Payen D, Mebazaa A. Cardiac and renal effects of levosimendan, arginine vasopressin, and norepinephrine in lipopolysaccharide-treated rabbits. Anesthesiology 2005 103 : 514 21.
32. Hiltebrand LB, Krejci V, Sigurdsson GH. Effects of dopamine, dobutamine, and dopexamine on microcirculatory blood flow in the gastrointestinal tract during sepsis and anesthesia. Anesthesiology 2004 100 : 1188 97.
33. Bloom IT, Bentley FR, Wilson MA, Garrison RN. In vivo effects of endothelin on the renal microcirculation. J Surg Res 1993 54 : 274 80.
34. Inscho EW, Imig JD, Cook AK, Pollock DM. ETA and ETB receptors differentially modulate afferent and efferent arteriolar responses to endothelin. Br J Pharmacol 2005 146 : 1019 26.
35. Nitescu N, Grimberg E, Ricksten SE, Herlitz H, Guron G. Endothelin B receptors preserve renal blood flow in a normotensive model of endotoxin-induced acute kidney dysfunction. Shock 2007, publish ahead of print.
36. Backer A, Bokemeyer D, Kramer HJ. Endothelin synthesis and receptors in porcine kidney. Acta Physiol Scand 2001 171 : 105 12.
37. Hoffman A, Abassi ZA, Brodsky S, Ramadan R, Winaver J. Mechanisms of big endothelin-1-induced diuresis and natriuresis: role of ET(B) receptors. Hypertension 2000 35 : 732 9.
38. Kon V, Yoshioka T, Fogo A, Ichikawa I. Glomerular actions of endothelin in vivo. J Clin Invest 1989 83 : 1762 7.
39. Sasser JM, Sullivan JC, Hobbs JL, Yamamoto T, Pollock DM, Carmines PK, Pollock JS. Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol 2007 18 : 143 54.
40. Granfeldt A, Ebdrup L, Tonnesen E, Wogensen L. Renal cytokine profile in an endotoxemic porcine model. Acta Anaesthesiol Scand 2008 52 : 614 20.
41. Alexander BT, Cockrell KL, Rinewalt AN, Herrington JN, Granger JP. Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension. Am J Physiol Regul Integr Comp Physiol 2001 280 : R1388 92.
42. Herizi A, Jover B, Bouriquet N, Mimran A. Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade. Hypertension 1998 31 : 10 4.
43. Rossi GP, Andreis PG, Neri G, Tortorella C, Pelizzo MR, Sacchetto A, Nussdorfer GG. Endothelin-1 stimulates aldosterone synthesis in Conn's adenomas via both A and B receptors coupled with the protein kinase C- and cyclooxygenase-dependent signaling pathways. J Investig Med 2000 48 : 343 50.
44. Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibe M. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 1994 199 : 1461 5.
45. Wong F, Moore K, Dingemanse J, Jalan R. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. Hepatology 2008 47 : 160 8.